| Dear valued authors, reviewers, and editorial board members, |
| On behalf of my editorial team, I am pleased to announce that The Lancet Oncology's impact factor has increased to 25·12, retaining our position as the global leader in clinical oncology research. |
We would like to thank you - our valued authors, reviewers, and editorial board members - for your continued support in making the journal a trusted, authoritative, and independent voice in the global field of clinical oncology. This result is evidence of the value clinicians and researchers alike place on the content published inThe Lancet Oncology.
|
To view the articles that contributed most to our new impact factor, please click the button to the right of this message.
|
| I hope you will enjoy reading these papers and I look forward to our continued collaboration in the years to come. |
| Yours sincerely, |
 |
David Collingridge
Editor, The Lancet Oncologyhttp://www.thelancet.com/journals/lanonc/issue/current |
|
|
No comments:
Post a Comment